Americans with local advanced or metastatic bladder cancer can now turn to a new first-line treatment for their disease—a drug combination that shows better outcomes compared to chemotherapy.
The FDA approved the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) for patients, regardless of their cisplatin eligibility, following a study showing its efficacy. The combination previously received accelerated FDA approval for patients who could not receive cisplatin-containing chemotherapy.
